Candidemia Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Candidemia market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Cidara Therapeutics, Mycovia Pharmaceuticals, Scynexis, GSK, Basilea Pharmaceutica, Pfizer, Astellas Pharma Inc, Gilead Sciences, Scynexis, Inc., Merck Sharp & Dohme LLC

[Nevada, United States] - DelveInsight's "Candidemia Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Candidemia, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Candidemia Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/candidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Candidemia Market Report:
The Candidemia market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In July, 2024: announced that a multicenter, open-label, non-comparator, single-arm study to evaluate the efficacy, safety, tolerability and PK (pharmacokinetics) of oral SCY-078 as an emergency use treatment for patients with a documented Candida auris infection.
In July, 2024: Mundipharma Research Limited announced that the purpose of their study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared to the standard antimicrobial regimen.
In June, 2024: Basilea Pharmaceutica announced that a multicenter, open-label, single arm study to evaluate the efficacy and safety of APX001 for the treatment of candidemia and/or invasive candidiasis caused by C. auris in patients aged 18 years and over with limited antifungal treatment options.
In May, 2024: Fujian Shengdi Pharmaceutical Co., Ltd. announced that the purpose of their study is to evaluate the efficacy and safety of intravenous HRS9432 in patients with candidemia and/or invasive candidiasis
In 2022, nearly 68.6% of incident candidemia patients were males whereas nearly 31.4% were females, in Japan.
The incident population of candidemia in Japan was approximately 901 cases in 2022.
Among EU4 and the UK, the UK had the lowest incident population with approximately 2,384 cases in 2022.
In 2022, incident cases of candidemia in the US varied according to gender with male predominance; approximately 13,059 males and 10,642 females. These cases are expected to increase by 2032.
Key Candidemia Companies are as follows: Cidara Therapeutics, Mycovia Pharmaceuticals, Scynexis, GSK, Basilea Pharmaceutica, Pfizer, Astellas Pharma Inc, Gilead Sciences, Scynexis, Inc., Merck Sharp & Dohme LLC
Key Candidemia Therapies are as follow: APX001, Anidulafungin, Micafungin, Caspofungin, AmBisome, SCY-078, Fluconazole, Micafungin, Rezafungin for Injection, Caspofungin, Fluconazole, MK0991
Launching multiple stage Candidemia pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Candidemia market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/candidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Candidemia Overview:
Candidemia is a serious, life-threatening bloodstream infection and possibly the fourth most common all-type bloodstreaminfections seen in the intensive care unit setting. The incidence of Candida bloodstream infection is bimodal, with the elderly andvery young having the highest risk of any population suffering from this disease.

Candidemia Epidemiology Segmentation:
The Candidemia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Candidemia Total Incident cases
Candidemia Age-specific cases
Candidemia Gender-specific cases
Candidemia Treated cases

For more information about Candidemia companies working in the treatment market, visit https://www.delveinsight.com/sample-request/candidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Candidemia Market Insights
The candidemia market is expected to experience significant growth during the forecast period (2024-2034). This is a direct consequence of various market-driving factors such as the rising incidence of candidemia, increasing susceptible immune-compromised patient pool, increasing awareness of the disease, and the development of innovative treatment options.
The current candidemia market is dominated by big pharmaceutical companies like Cidara Therapeutics, Mycovia Pharmaceuticals, and Scynexis offering various approved therapies such as REZZAYO, VIVJOA, and BREXAFEMME for the treatment of candidemia and candidiasis
Despite advances in diagnosis and treatment, the prognosis of candidemia remains high and far from desirable, with an overall mortality of nearly 30%, due to limitations in diagnostic tests, challenges concerning the timing of antifungal therapy initiation, and the development of new and innovative treatment approaches.

Candidemia Drugs Uptake
Drugs such as caspofungin, micafungin, and anidulafungin are the frontline therapies for candidemia. These are well-tolerated and effective against many Candida species, including resistant strains like C. glabrata.
Fluconazole remains a widely used treatment, particularly in resource-limited settings due to its cost-effectiveness and oral availability. However, its utility is waning with the rise of azole-resistant Candida species.
Once the gold standard for treating systemic fungal infections, amphotericin B's use has declined due to its nephrotoxicity. Liposomal formulations of amphotericin B are still used in severe or refractory cases.
Rezafungin: A new echinocandin in development, with an extended half-life allowing for once-weekly dosing, is in clinical trials and may improve patient compliance and outcomes.
Monoclonal antibodies: These are being investigated for their potential to target Candida antigens and offer a novel therapeutic approach, particularly for multidrug-resistant strains like C. auris.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/candidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Candidemia Therapies and Key Companies:
APX001: Basilea Pharmaceutica
Anidulafungin: Pfizer
Micafungin, Caspofungin: Astellas Pharma Inc
AmBisome: Gilead Sciences
SCY-078, Fluconazole, Micafungin: Scynexis, Inc.
Rezafungin for Injection, Caspofungin, Fluconazole: Cidara Therapeutics Inc.
MK0991: Merck Sharp & Dohme LLC

Candidemia Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Candidemia.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/candidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Candidemia Market Drivers:
Rising Incidence of Immunocompromised Patients
Increased Awareness and Early Diagnosis
Development of Novel Antifungal Therapies
Hospital Infection Control Programs

Candidemia Market Barriers:
Antifungal Drug Resistance
High Treatment Costs
Delayed Diagnosis
Adverse Effects of Antifungal Therapies

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/candidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Candidemia Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Candidemia Companies: Cidara Therapeutics, Mycovia Pharmaceuticals, Scynexis, GSK, Basilea Pharmaceutica, Pfizer, Astellas Pharma Inc, Gilead Sciences, Scynexis, Inc., Merck Sharp & Dohme LLC
Key Candidemia Therapies: APX001, Anidulafungin, Micafungin, Caspofungin, AmBisome, SCY-078, Fluconazole, Micafungin, Rezafungin for Injection, Caspofungin, Fluconazole, MK0991
Candidemia Therapeutic Assessment: Current marketed and emerging therapies
Candidemia Market Dynamics: Candidemia Market drivers and Candidemia barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Candidemia Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Candidemia market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/candidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1 Key Insights
2 Report Introduction
3 Candidemia Market Overview at a Glance
4 Epidemiology and Market Methodology
5 Executive Summary
6 Key Events
7 Disease Background and Overview
8 Epidemiology and Patient Population
9 Patient Journey
10 Marketed Drugs
11 Emerging Therapies
12 Candidemia: Seven Major Market Analysis
13 Key Opinion Leaders' Views
14 Unmet Needs
15 SWOT Analysis
16 Market Access and Reimbursement
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.